Mylan Inc. yesterday promoted Chief Operating Officer Heather Bresch to president of the Cecil generic drug maker. Rajiv Malik, head of Mylan's global technical operations, replaced her as COO.
"Their track record of producing results and executing flawlessly as well as their exemplary leadership skills has earned them the right to these new roles," CEO Robert J. Coury said in a statement.
Ms. Bresch, 40, who joined the company as a data entry clerk in 1992, was named COO in October 2007. She is the daughter of West Virginia Gov. Joe Manchin and last year was the center of an M.B.A. degree scandal at West Virginia University.
Her promotion comes as Mylan, the world's third-largest generic drug company, is being investigated by the U.S. Food and Drug Administration. The probe follows a story in Sunday's Pittsburgh Post-Gazette based on a Mylan internal report that said workers at the company's Morgantown, W.Va., plant had routinely sidestepped computer-generated warnings about potential problems with the medications they were making. The report did not say what drugs were involved.
Mylan's report said the problem was "pervasive" and occurred on all three shifts at the plant, which makes an estimated 19 billion doses annually. It did not say how long the unauthorized practice had been going on.
The breach in quality control was "very serious," involving "falsifying information" and "altering product" but did not affect the quality of the medications, the report stated. The report did not say how Mylan determined that quality was not compromised.
Former FDA inspectors and industry consultants who reviewed Mylan's internal report for the newspaper said the breach of protocol raised troubling questions about the integrity and oversight of the plant's quality control operations.
Mylan has not responded to numerous Post-Gazette requests for comment.
On Tuesday, Mylan issued a statement asserting that the FDA had closed its investigation after visiting the plant Monday and finding "a minor standard operating procedure deviation." In the statement, Mr. Coury said the agency's actions "reaffirm Mylan's long-standing reputation as one of the industry's highest quality manufacturers."
Mylan's statement that the probe was over and that the plant had been cleared was refuted two hours later by FDA assistant commissioner Steven Solomon.
"The investigation is ongoing, and the agency has formed no conclusions at this time. Statements to the contrary are untrue," Mr. Solomon said.
Analysts were at a loss over what to make of the contradictory statements about the investigation.
"You can't make this stuff up, and it always seems to happen to [Mylan]," Natixis Bleichroeder analyst Corey Davis wrote in a note to clients yesterday.
Analysts have criticized Mr. Coury in the past for what Mr. Davis described yesterday as "a litany of botched communications."
On Tuesday, Mylan told other media and the investment community that Mr. Solomon must have been misinformed.
The FDA, however, said there had been no mix-up and reiterated that the investigation was ongoing.
Marla Phillips, director of Xavier University's Pharmaceutical Technology Institute, said she was stunned by the dueling statements.
Dr. Phillips, a former pharmaceutical industry quality control manager, said CEOs usually do not make public statements on unresolved regulatory matters.
"To have such an arrogant statement from the CEO that is then refuted by the FDA is unbelievable," Ms. Phillips said.
Mylan said yesterday that as president, Ms. Bresch would take on expanded leadership duties related to day-to-day operations.
When the company announced her promotion to COO in 2007, she stated that she had an M.B.A. degree from WVU.
Following a Post-Gazette story questioning the degree, an investigative panel concluded that after the newspaper had asked the school to verify her claim, university officials falsified her academic records to make it appear she finished the degree. The changes included adding 22 credits and grades "pulled from thin air" to her transcript. Officials then awarded her a degree retroactively that she did not earn.
After the panel's report, the degree was revoked and WVU's president, Michael Garrison, and the university's provost and business school dean resigned.
Mylan's shares closed yesterday at $12.91, up 35 cents, or 3 percent.




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.